Drug development in chronic obstructive pulmonary disease (COPD) has been characterised by unacceptably high failure rates. In addition to the poor sensitivity in forced expiratory volume in one second (FEV1), numerous causes are known to contribute to this phenomenon, which can be clustered into drug-, disease- and design-related factors. Here we present a model-based approach to describe disease progression, treatment response and dropout in clinical trials with COPD patients

Danhof, M

Della Pasqua, O

Facius, A

Maas, HJ

Musuamba, FT

Teutonico, D

Yang, S

English

PubMed

F. T. Musuamba

D. Teutonico

H. J. Maas

A. Facius

S. Yang

M. Danhof

O. Della Pasqua

Springer - Publisher Connector

Prediction of Disease Progression, Treatment Response and Dropout in Chronic Obstructive Pulmonary Disease (COPD)

UCL Discovery

A joint model for nonlinear longitudinal data with informative dropout.

American Thoracic Society. Standardization of spirometry,

Bronchodilator efficacy of tiotropiumformoterol via single pressurized meter dose inhaler (pmdi) versus tiotropium alone in COPD. Pulm Pharmacol Ther.

Chronic treatment with indacaterol and airway response to salbutamol in stable COPD.

Comparison of four basic models of indirect pharmacologic responses.

Computing normalized prediction distribution errors to evaluate nonlinear mixed effects models: the npde add-on package for R. Comput Methods Prog Biomed.

Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res.

COPD and gender differences: an update. Transl Res.

Core Team. R: a language and Environment for Statistical computing.

Danhof M,etal.Markers ofdiseaseseverityinchronicobstructivepulmonary disease Pulm. Pharmacol Ther.

Dose–response study of inhaled salmeterolinasthmaticpatients with24-hour spirometry and Holter monitoring. Ann Allergy.

Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study. Respir Res.

Exposure-Response Working Group, Medical Policy Coordinating Committee. Guidance for industry. Exposure-response relationships — study design, data analysis, and regulatory applications. Food and Drug Administration,

Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials.

Inference and missing data.

Informative drop-out in longitudinal data analysis. Appl Stat.

Kinetics of pharmacologic response. Pharmacol Ther.

Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther.

MallinckrodtCH,ClarkWS,DavidSR.Accountingfordropoutbias using mixed-effets models.

Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res.

Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

Modeling of dose–response-time data: four examples of estimating the turnover parameters and generating kinetic functions from the response profiles. Biopharm Drug Dispos.

Modeling response time profiles in the absence of drug concentrations; definition and performance evaluation of the K-PD model.

Novel outcomesandend points: biomarkers in chronic obstructive pulmonary disease clinical trials.

Pathogenesis of chronic obstructive pulmonary disease.

Patient specific multiscale modelling for plaque formation and progression.

Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients.

Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther.

Prognostic factors in chronic obstructive pulmonary disease. Curr Opin Pulm Med.

PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed.

Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Prog Biomed.

Prediction of disease progression, treatment response and dropout in chronic obstructive pulmonary disease (COPD).

PURPOSE: Drug development in chronic obstructive pulmonary disease (COPD) has been characterised by unacceptably high failure rates. In addition to the poor sensitivity in forced expiratory volume in one second (FEV1), numerous causes are known to contribute to this phenomenon, which can be clustered into drug-, disease- and design-related factors. Here we present a model-based approach to describe disease progression, treatment response and dropout in clinical trials with COPD patients. METHODS: Data from six phase II trials lasting up to 6months were used. Disease progression (trough FEV1 measurements) was modelled by a time-varying function, whilst the treatment effect was described by an indirect response model. A time-to-event model was used for dropout RESULTS: All relevant parameters were characterised with acceptable precision. Two parameters were necessary to model the dropout patterns, which was found to be partly linked to the treatment failure. Disease severity at baseline, previous use of corticosteroids, gender and height were significant covariates on disease baseline whereas disease severity and reversibility to salbutamol/salmeterol were significant covariates on Emax for salmeterol active arm. CONCLUSION: Incorporation of the various interacting factors into a single model will offer the basis for patient enrichment and improved dose rationale in COPD.</p

Musuamba, F.T.

Teutonico, D.

Maas, H.J.

Facius, A.

Yang, S.

Danhof, M.

Della Pasqua, O.

NARCIS 

PURPOSE: Drug development in chronic obstructive pulmonary disease (COPD) has been characterised by unacceptably high failure rates. In addition to the poor sensitivity in forced expiratory volume in one second (FEV1), numerous causes are known to contribute to this phenomenon, which can be clustered into drug-, disease- and design-related factors. Here we present a model-based approach to describe disease progression, treatment response and dropout in clinical trials with COPD patients. METHODS: Data from six phase II trials lasting up to 6months were used. Disease progression (trough FEV1 measurements) was modelled by a time-varying function, whilst the treatment effect was described by an indirect response model. A time-to-event model was used for dropout RESULTS: All relevant parameters were characterised with acceptable precision. Two parameters were necessary to model the dropout patterns, which was found to be partly linked to the treatment failure. Disease severity at baseline, previous use of corticosteroids, gender and height were significant covariates on disease baseline whereas disease severity and reversibility to salbutamol/salmeterol were significant covariates on Emax for salmeterol active arm. CONCLUSION: Incorporation of the various interacting factors into a single model will offer the basis for patient enrichment and improved dose rationale in COPD.Pharmacolog

Leiden University Scholary Publications

Prediction of disease progression, treatment response and dropout in chronic obstructive pulmonary disease (COPD).

Abstract

Similar works

Full text

Available Versions

Springer - Publisher Connector

UCL Discovery

NARCIS

Leiden University Scholary Publications